Understand the source comparison
Best Peptides for Fertility: Research Comparison
The table below summarizes key peptide candidates, their primary mechanism, typical research dosing ranges, and evidence quality. This comparison is for educational reference. Dosing decisions in human fertility protocols require clinical oversight. Gonadoreli
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below summarizes key peptide candidates, their primary mechanism, typical research dosing ranges, and evidence quality. This comparison is for educational reference. Dosing decisions in human fertility protocols require clinical oversight.
- Gonadorelin (GnRH)
- Restores pulsatile LH/FSH secretion via GnRH receptor activation
- 5–10mcg IV every 90 minutes (pulsatile pump)
- High. Multiple RCTs in hypothalamic amenorrhea
- Gold standard for restoring ovulation in women with hypothalamic dysfunction; requires pulsatile delivery
- Kisspeptin-10
- Activates GPR54 receptors to trigger endogenous GnRH neuron firing
- 6.4–12.8nmol/kg subcutaneous bolus
- Moderate. Phase 2 trials in IVF triggering
- Promising for IVF trigger with lower OHSS risk; half-life limits use to acute dosing
- Thymosin Alpha-1
- Promotes Treg differentiation and immune tolerance at implantation site
- 1.6mg subcutaneous twice weekly
- Moderate. Cohort studies in recurrent implantation failure
- Statistically significant improvement in women with elevated NK cells; mechanism well-characterized
- VIP (Vasoactive Intestinal Peptide)
- Shifts decidual cytokine profile to anti-inflammatory (IL-10, TGF-β)
- 200mcg intranasal daily
- Low. Pilot trials only
- Mechanistically sound but limited clinical data; intranasal delivery bypasses hepatic metabolism
- IGF-1 LR3
- Enhances FSH receptor expression and aromatase activity in granulosa cells
- 20–40mcg subcutaneous daily
- Low. Animal models and small cohort studies
- Improves follicle recruitment in diminished ovarian reserve; human RCTs lacking
- Sermorelin (GHRH fragment)
- Stimulates endogenous GH secretion to upregulate ovarian IGF-1
- 200–300mcg subcutaneous before bed
- Moderate. Meta-analyses support GH co-treatment in poor responders
- Preserves pulsatile GH rhythm; indirect mechanism requires 4–6 week lead time